Summary

The 7 major diabetic peripheral neuropathy markets reached a value of US$ 2,903.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,365.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.74% during 2024-2034.

The diabetic peripheral neuropathy market has been comprehensively analyzed in IMARC's new report titled "Diabetic Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic peripheral neuropathy refers to a medical condition in which nerve damage occurs as a complication of diabetes. It affects the nerves, mainly in the feet and hands, and can be motor, sensory, or both. The most common indications associated with this illness include a feeling of tingling or numbness in the feet or hands, burning, stabbing, or shooting pain in the affected areas, ulcers, infections, loss of coordination and balance, muscle weakness, particularly in the feet, etc. Over time, the condition can lead to serious complications, such as foot ulcers, infections, and even amputations, if left untreated. The diagnosis of diabetic peripheral neuropathy generally requires a combination of the patient's clinical features, medical history, and a physical exam. An electromyography (EMG), in which a tiny needle is inserted through the skin to measure the electrical activities of the muscle, is also utilized to evaluate nerve function. The healthcare provider may further perform specific investigations, such as filament testing, sensory tests, nerve conduction studies, etc., to confirm the diagnosis and rule out other possible conditions.

The rising cases of uncontrolled high blood sugar levels, which weaken the capillary walls and damage nerves, are primarily driving the diabetic peripheral neuropathy market. Moreover, the increasing incidences of numerous associated risk factors, including excessive alcohol consumption, chronic inflammation, autoimmune disorders, smoking, kidney diseases, etc., are also augmenting the market growth. Apart from this, the widespread adoption of effective drugs, like anti-seizures and tricyclic antidepressants, to ease nerve pain as well as improve the quality of life in patients is creating a positive outlook for the market. Furthermore, the emerging popularity of pharmacotherapy coupled with certain lifestyle modifications, such as smoking cessation, regular exercises, consumption of a healthy or balanced diet, etc., is also bolstering the market growth. Additionally, various key players are making extensive investments in research initiatives to develop novel, cost-effective topical therapies for treating the ailment. This, in turn, is acting as another significant growth-inducing factor. Moreover, the inflating usage of transcutaneous electrical nerve stimulation therapy, which aims to alleviate symptomatic pain by stimulating sensory nerves, is expected to drive the diabetic peripheral neuropathy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the diabetic peripheral neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic peripheral neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic peripheral neuropathy market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the diabetic peripheral neuropathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the diabetic peripheral neuropathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current diabetic peripheral neuropathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the diabetic peripheral neuropathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the diabetic peripheral neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the diabetic peripheral neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with diabetic peripheral neuropathy across the seven major markets?
What is the size of the diabetic peripheral neuropathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of diabetic peripheral neuropathy?
What will be the growth rate of patients across the seven major markets?

Diabetic Peripheral Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for diabetic peripheral neuropathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic peripheral neuropathy market?
What are the key regulatory events related to the diabetic peripheral neuropathy market?
What is the structure of clinical trial landscape by status related to the diabetic peripheral neuropathy market?
What is the structure of clinical trial landscape by phase related to the diabetic peripheral neuropathy market?
What is the structure of clinical trial landscape by route of administration related to the diabetic peripheral neuropathy market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Diabetic Peripheral Neuropathy - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Diabetic Peripheral Neuropathy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Diabetic Peripheral Neuropathy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Diabetic Peripheral Neuropathy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Diabetic Peripheral Neuropathy - Unmet Needs

10 Diabetic Peripheral Neuropathy - Key Endpoints of Treatment

11 Diabetic Peripheral Neuropathy - Marketed Products
11.1 List of Diabetic Peripheral Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1 Lyrica (Pregabalin) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Cymbalta (Duloxetine) - Eli Lilly and Company
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Diabetic Peripheral Neuropathy - Pipeline Drugs
12.1 List of Diabetic Peripheral Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Engensis - Helixmith
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ricolinostat - Regenacy Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MT8554 - Mitsubishi Tanabe Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 LX9211 - Lexicon Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Cebranopadol - Tris Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Diabetic Peripheral Neuropathy - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Diabetic Peripheral Neuropathy – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Diabetic Peripheral Neuropathy - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Diabetic Peripheral Neuropathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Diabetic Peripheral Neuropathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Diabetic Peripheral Neuropathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Diabetic Peripheral Neuropathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Diabetic Peripheral Neuropathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Diabetic Peripheral Neuropathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Diabetic Peripheral Neuropathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Diabetic Peripheral Neuropathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Diabetic Peripheral Neuropathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Diabetic Peripheral Neuropathy - Access and Reimbursement Overview

16 Diabetic Peripheral Neuropathy - Recent Events and Inputs From Key Opinion Leaders

17 Diabetic Peripheral Neuropathy Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Diabetic Peripheral Neuropathy Market – Strategic Recommendations

19 Appendix